EMA decision expected in H2 2021 First Marketing Authorisation Application for a gene therapy treating a mitochondrial disease U.S. FDA submission on track for H2 2021 Regulatory News: GenSight Biologics (Paris:SIGHT) ((Euronext: SIGHT, GREY: GSGTF , PEA-PME eligible)), a biopharma company focused on discovering and developing innovative gene therapies […]